Interim report
Page 1
YH/SE/80/2025-26 February 05, 2026 The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051, India Symbol: YATHARTH ISIN: INE0JO301016 Dept. of Listing Operations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, India Scrip Code: 543950 ISIN: INE0JO301016 Subject: Outcome of Board Meeting – Financial Results Dear Sir/Madam, Pursuant to Regulation 30 & Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Yatharth Hospital & Trauma Care Services Limited (“Company”) at its meeting held today i.e. February 05, 2026, has inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine months ended on December 31, 2025. The copy of the said financial results alongwith Limited Review Report issued by M/s. MSKA & Associates LLP, Statutory Auditor of the Company, is enclosed herewith. The above information will also be made available on website of the Company at https://www.yatharthhospitals.com/investors The Board Meeting commenced at 1:10 PM (IST) and concluded at 1:46 PM (IST). This is for your kind information and records. Thanking You Yours Faithfully, For Yatharth Hospital & Trauma Care Services Limited Ritesh Mishra Company Secretary & Compliance Officer M. No. A51166 Encl.: A/a
Page 2
MSKA &: Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants Magnum Global Park Unit No-2101-211 SA & B, Floor 21 Sector-58, Arch View Drive Gurugram 122011, INDIA Independent Auditor's Review Report on Standalone unaudited financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and year to date ended December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Yatharth Hospital & Trauma Care Services Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Yatharth Hospital ft Trauma Care Services Limited (hereinafter referred to as 'the Company') for the quarter ended December 31, 2025 and the year to-date results for the period from April 01, 2025 to December 31, 2025 ('the Statement') attached herewith , being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations'). 2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The Statement of the Company for the quarter and nine month period ended December 31, 2024, and year ended March 31, 2025 were reviewed / audited by another auditor whose reports dated January 27, 2025 and May 26, 2025 expressed an unmodified conclusion/opinion on that Statement. For MS KA & Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants ICAI Firm Registration No. 105047W /W101187 Sumit Verma Membership No.: 509426 UDIN: 26509426XHEIPA4799 Place: Gurgaon Date: February 05, 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT-3789 Ahmedabad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Hyderabad I Kochi I Kolkata I Mumbai I Pune www.mska.in
Page 3
YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED Registered Office : JA 108 DLF Tower A, Jasola District Centre, South Delhi, Delhi 110025, India Corporate Office: Second Floor Sovereign Capital Gate, FC 12 Sector 16A, Nolda Sector 16, Gautam Buddha Nagar, Nolda, Uttar Pradesh, India, 201301 Website: www.yatharthhospitals.com Email: cs@yatharthhospitals.com CIN: L85110DL2008PLC174706 STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 (INR in Millions except Shares and EPS) Standalone Quarter Ended Nine Months Ended Year Ended Particulars 31 Dec'2025 30 Sep'2025 31 Dec'2024 31 Dec'2025 31 Dec'2024 31 Mar'2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Revenue from operations 1,581.50 1,372.87 1,104.11 4,255.81 3,422.49 4,542.41 II Other income 54.70 61 .50 31.54 188.78 75.94 116.93 Ill Total Income (1+11) 1,636.20 1,434.37 1,135.65 4,444.59 3,498.43 4,659.34 IV Expenses Purchase of drues, consumables and imolants 255.91 286.17 195.42 824.01 659.94 932.49 Change in inventories of drugs, consumables and implants 48.88 (10.36) 1.26 38.50 (12.91) (53.63) Employee benefits expense 316.28 277. 96 208.81 829.62 609.98 823.89 Finance costs 9.12 1.85 1.46 12.54 4.64 6.16 Depreciation and amortisation expenses 90.00 63.18 51.85 200.05 139.54 186.63 Other expenses 594.95 549.60 380.63 1,578.17 1,213.05 1,569.48 Total expenses (IV) 1,315.14 1,168.40 839.43 3,482.89 2,614.24 3,465.02 V Profit before tax (Ill - IV) 321.06 265, 97 296.22 961.70 884.19 1,194.32 VI Tax expense Current tax 85.48 56.09 74.99 243.22 225.42 314.91 Income tax of earlier years (7.19) (7.19) (0.21) (0.21) Deferred tax 3.84 3.47 (1.30) 9.13 1.02 2.69 Total tax expense (VI) 82.13 59.56 73.69 245.16 226.23 317.39 VII Profit after tax for the period / year (V • VI) 238.93 206.41 222.53 716.54 657,96 876,93 VIII Other Comprehensive Income Items that will not be reclassified to profit or loss Remeaurement gain on defined beJ'lefit plans 1.67 0.61 1.20 1.43 0.15 2.20 Income tax relating to items that will not be reclassified to profit or loss (0.42) (0.15) (0.30) (0.36) (0.04) (0.55) Total other comprehensive income for the period/ year (VIII) 1.25 0.46 0.90 1.07 0.11 1.65 IX Total Comprehensive Income for the period/ year (VII + VIII) 240.18 206.87 223.43 717.61 658.07 878.58 X Paid up Equity Share Capital (Face Value Rs. 10/· per share) 963.54 963,54 963.54 963,54 963.54 963.54 XI Other equity 14,287.90 XIII Earnings per equity share of Rs. 10/- per share (Not annualised except for the year ended 31 March 2025) Basic (ir. INR) 2.48 2.14 2.60 7.44 7.64 9.89 Diluted (in INR) 2.48 2.14 2.60 7.44 7.64 9.89 ~
Page 4
Notes to the unaudited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the Quarter and Year to date ended December 31 , 2025 1. The unaudited standalone financial results ('the statement') of Yatharth Hospital & Trauma Care Services Limited ('the Company') for the Quarter and Year to date ended December 31 , 2025 have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on February 5, 2026. The Statutory Auditors have carried out limited review of the above statement. 2. The Chief operating decision maker (CODM- CEO) examines the Company performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The Company operates in the India and it constitutes the single geographical segment. 3. During October 2023, The Income Tax Department ("the Department") conducted searc.hes under section 132 of the Income tax act at the premises belonging to the Company, it's subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provi<led the fullest co-operation. Further, the Department had ordered for provisional attachment under Section 281 B of the Income Tax Act, of some properties , bank deposits, cash balance and investment in subsidiary companies. During the current quarter, the department has released the provisional attachments on properties , bank deposits and cash balance as stated above. Subsequent to the reporting date, the Department has issued the Assessment Order for AV 2024- 25 and the Company has filed appeal against the said order. Based on internal assessment, the Company believes that no material liability is expected in this matter. Accordingly, no provision is required to be made in the statement in this regard. (This Space has been intentionally left blank)
Page 5
5. During the previous year, the Company raised further funds through qualified institutional placements (QIP). During QIP 105,04, 124 Equity Shares issued at a price of 595.00 per equity share for amount aggregating to Rs 6249. 95 million was made by Company. The utilization of the QIP is proceeds during the quarter is as follows: ( all firnres in million) Amount Amount Amount Amount Total as per utilized at utilized utilized at unutilized Object as per final the during the the end of amount as at prospectus offer beginning of reported the the end of document the reported quarter reported the reported quarter quarter quarter Repayment I pre- payment, in full or in part, of certain outstanding 956.80 956.80 - 956.80 - borrowings availed by the Company and Subsidiary Funding in part the acquisition costs of two hospitals situated 2,173.85 2,173.19 0.66 2,173.85 at Model Town, Delhi - and Faridabad, Haryana Funding for purchase of medical 1,517.36 836.39 293.31 1,129.70 387.66 equipment's General corporate 1,390.99 purposes 1,252.27 138.72 1,390.99 Sub-total 6,039.00 5,218.65 432.69 5,651.34 387.66 Issue expenses 210.95 210.95 - 210.95 - Total 6,249.95 5,429.60 432.69 5,862.29 387.66 6. Subsequent to the reporting date, the Company has acquired a hospital (running under the brand name of "Shantived Institute of Medical Sciences") situated at Agra, Uttar Pradesh, w.e.f February 01, 2026. The said entity has hospital with 150 operational beds (expandable upto 250 beds). 7. On November 21, 2025, the Government of India notified the four Labour Codes-namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 existing labour laws. The Ministry of Labour Et Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from the changes in regulations.
Page 6
The Company continues to monitor the finalisation of the Central and State Rules and any further clarifications issued by the Government and will assess and account for the impact, if any, arising from such developments as and when they occur. 8. The financial results of the Company for the quarter and nine months period ended December 31, 2024, and year ended March 31, 2025 were reviewed I audited by another auditor whose report dated January 27, 2025 and May 26, 2025, respectively and expressed an unmodified opinion on that Statement on results/financial statements. 9. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable. 10. The aforesaid Statement is available on the Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com ). On behalf of the Board of Directors Yatharth Hospital & Trauma C ~/ Dr. Ajay Kumar Tyagi Chairman and Whole-time Director Place: Noida Dated: February 5, 2026
Page 7
MSKA & Associates LLP Magnum Global Park Unit No-2101-2115A & B, Floor 21 Sector-58, Arch View Drive Gurugram 122011 , INDIA (Formerly known as MS KA & Associates) Chartered Accountants Independent Auditor's Review Report on consolidated unaudited financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and year to date ended December 31, 2025 pursuant to the Regulation 33 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Yatharth Hospital & Trauma Care Services Limited 1. We have reviewed the accompanying Statement of consolidated unaudited financial results of Yatharth Hospital & Trauma Care Services Limited (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2025 and the year to-date results for the period from April 01, 2025 to December 31 , 2025 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations'). 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable. 4. This Statement includes the results of the Holding Company and the following subsidiaries: Sr. No Name of the Entity Relationship with the Holding Company 1. 2. 3. 4. 5. Ahmedabad I AKS Medical & Research Private Limited Wholly Owned Subsidiary Sanskar Medica India Limited Wholly Owned Subsidiary Ramraja Multispecialty Hospital & Trauma Centre Wholly Owned Subsidiary Private Limited Pristine lnfracon Private Limit ed Wholly Owned Subsidiary MGS lnfot ech Research And Solutions Private Limited Subsidiary Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra; :~ ~ urugram ::= Tel: +91 22 6974 0200 I LLPIN: ACT-3789 -~ Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Hyderabad I Kechi I Kolkata I Mumbai I P n 'l!:l!I"""--"=.!!!
Page 8
MSKA & Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. We did not review the interim financial results of four subsidiaries included in the Statement, whose interim financial results reflects total revenues of Rs. 653. 16 millions and Rs. 1,556.17 millions, total net profit after tax of Rs. 10. 54 millions and Rs. 107.43 millions and total comprehensive income of Rs. 11.21 millions and Rs. 107.71 millions for the quarter ended December 31, 2025 and for the period from April 01, 2025 to December 31, 2025, respectively, as considered in the Statement. These interim financial results have been reviewed by the other auditor whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditor. 7. The Consolidated financial results of the Group for the quarter and nine month period ended December 31, 2024, and year ended March 31, 2025 were reviewed by another auditor whose report dated January 27, 2025 and May 26, 2025 expressed an unmodified conclusion/ opinion on that statement . For MS KA & Associates LLP (Formerly known as MS KA & Associates) Chartered Accountants ICAI Firm Registration No. 105047W /W101187 Sumit Verma Partner Membership No.: 509426 UDIN: 26509426TXUXUK6871 Place: Gurugram Date: February 05, 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 I LLPIN: ACT-3789 Ahmedabad I Bengaluru I Chandigarh I Chennai I Coimbatore I Goa I Gurugram I Hyderabad I Kochi I Kolkata I Mumbai I Pune www.mska.in
Page 9
YATHARTH HOSPITAL a TRAUMA CARE SERVICES LIMITED Registered Office : JA 108 DLF Tower A, Jasola District Centre, South Delhi, Delhi 110025, India Corporate Office : Second Floor Sovereign Capital Gate, FC 12 Sector 16A, Nolda Sector 16, Gautam Buddha Nagar, Nolda, Utta r Pradesh, India, 201301 Websit e: www.yat harthh osp1ta1s.com Emall: cs@yatharthhospitals.com CIN: L8511 0DL2008PLC174706 STATEMENT Of UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 (INR in Million except Shares and EPS) Consolidated Quarte r Ended Nine Months Ended Year Ended Particulars 31 Dec'2025 30 Sep'2025 31 Dec'2024 31 Dec'2025 31 Dec'2024 31 Mar'2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Revenue from operati ons 3,204.71 2,794.21 2,191.55 8,576.63 6,487.06 8,804.87 II Other income 78.25 94.89 42.10 266.25 108.34 161.75 Ill Total Income (1+11) 3,282.96 2,889 .10 2,233.65 8,842.8 8 6,595 .40 8,966.62 IV Expenses Purchase of drugs, consumables and implants 584.24 625.57 395. 78 1,764.42 1,357.40 1,913.46 Change in inventories of drugs, consumables and implants 40.39 (61.58) 24.85 (40.68) (37.07) (128.17) Employee benefits expense 635.39 537.86 426.15 1,655.02 1,186.80 1,625.00 Finance costs 10.17 2.57 20.58 14.64 65.39 75.11 Depreciation and amorti sation expenses 239.60 189.31 169.13 578.10 443.02 571.72 Other expenses 1,202.20 1,047.14 795.60 3,165.30 2,347.78 3,192.11 Total expenses (IV) 2,711.99 2,340.87 1,832.09 7,136.80 5,36 3.32 7,249.23 V Profit / (loss) before excep tional Items and tax (Ill-IV) 570.97 548.23 401.56 1,706.08 1,232.08 1,717.39 VI Tax expense Current tax 151.01 110.96 112.05 408.03 354.07 491.62 Income tax of earlier years (6.80) 12.39 5.59 (0.19) (0.19) Deferred tax (4.07) 12.35 (15.40) 28.71 (40.07) (79.54) Total tax expense (VI) 140.14 135. 70 96.65 442.33 313.81 411.89 VII Profit after tax for the period / year (V-VI) 430.83 412.5 3 304. 91 1,263.75 918.27 1,305.5 0 Profit after tax for the period/ year attributable to: Owners of the Holding Company 453. 51 412.42 304.9 1 1,286.28 918.27 1,305.45 Non-controlling interests (22.68 ) 0.11 (22.53) 0.05 VIII Other Comprehensive Income Items that will not be reclassified to profit or loss Remeaurement gain on defined benefit plans 1.62 2.58 2.47 1.75 1.03 3.91 Income tax relating to items that will not be reclassified to profit or loss (0.42) (0.65) (0.62) (0.45) (0.26) (0.98) Total other comprehensive income for the period/ year (VIII) 1.20 1.93 1.85 1.30 0.77 2.93 IX Total Comprehensive Income for the period/ year (Vll+VIII) 432.03 414.46 306.76 1,265 .05 919.04 1,308.43 Total Comprehensive Income for the peri od/ year attributable to: Owners of the Holding Company 454.71 414.3 5 306.76 1,287.58 919.04 1,308.38 Non-controlling interests (22.68) 0.11 (22.53 ) - 0.05 X Paid up Equity Share Capital (Face Value Rs. 10/- per share) 963 .54 963.54 963.54 963.54 963.54 963.54 XI Other equity 15,091.05 XIII Earning s per equity share of Rs. 10/- per share (Not annualised except for the year ended 31 March 2025) Basic (in INR) 4. 71 4.28 3.57 13.35 10.67 14.72 Diluted (in INR) 4.7 1 4.28 3.57 13.35 10.67 14.72
Page 10
Notes to the unaudited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited for the Quarter and Year to date ended December 31 , 2025 1. The unaudited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries ('together referred as "Group'") for the Quarter and Year to date ended December 31, 2025, have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on February 5, 2026. The Statutory Auditors have carried out limited review of the above statement. 2. The Chief operating decision maker (CODM· CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The Group operates in the India and it constitutes the single geographical segment. 3. During October 2023, The Income Tax Department ("the Department") conducted searches under section 132 of the Income tax act at the premises belonging to the Holding Company and two of it's subsidiary companies (i.e. AKS Hospital & Research Centre Private Limited & Ramraja Multispeciality Hospital & Trauma Centre Private Limited) and the key managerial persons of the Group. The Group provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. Further, the Department had ordered for provisional attachment under Section 281 B of the Income Tax Act, of some properties , bank deposits, cash balance and investment in subsidiary companies. During the current quarter, the department has released the provisional attachments on properties , bank deposits and cash balance as stated above. Subsequent to the reporting date, the Department has issued the Assessment Order for AY 2024· 25 to the Holding Company and it's above said subsidiary companies and the respective Companies have filed appeal against the said order. Based on internal assessment, the Group believes that no material liability is expected in this matter. Accordingly, no provision is required to be made in the statement in this regard. (This Space has been intentionally left blank)
Page 11
4. During the earlier year (i.e. year ended March 31, 2024), the Holding Company has raised Rs. 6,100 million through the issues of 16,333,333 Equity Shares during IPO and 40,00,000 equity share during pre-lPO at price of Rs 300 per equity shares. The Holding Company got listed on BSE and NSE on August 7, 2023. The utilization of IPO proceeds during the quarter is as follows (net of IPO expenses): (all figures in million) Amount Amount Amount Amount Balance as as at the Objects proposed in utilized at utilized at utilized at end of as per the offer beginning of the end of the end of prospectus Document the reported the reported the reported the quarter quarter quarter reported quarter Repayment, in full or part, of certain borrowings availed 1,000.00 1,000.00 - 1,000.00 - by the Holding Company Repayment, in full or part, of certain 1,450.00 1,427.20 1,427.20 22.80 borrowings availed by the Group Funding capital expenditure, expenses of two hospitals namely Naida and Greater 256.44 256.44 - 256.44 -Naida Hospital Funding capital expenditure , expenses of subsidiaries; AKS 1,069.66 642.30 - 642.30 427.36 and Ramraja for respective hospital operated by them Funding inorganic growth initiatives through acquisiti ons 650.00 650.00 - 650.00 and other strategic initiatives General Corporate 1,271.00 1,236.70 1,236.70 34.30 - Purpose 5697.10 5,212.64 - 5, 212.64 484.46 Total
Page 12
5. ~uri_ng . the previous year, the Holding Company raised further funds through qualified mst1tut1onal placements (QIP). During QIP 105,04, 124 Equity Shares issued at a price of 595.00 per equity share for amount aggregating to Rs 6249.95 million was made by Holding Company. The utilization of the QIP is proceeds during the quarter is as follows: Object as per prospectus Repayment / pre payment, in full or in part, of certain outstanding borrowings availed by the Group Funding in part the acquisition costs of two hospitals situated at Model Town, Delhi and Faridabad, Haryana Funding for purchase of medical equipment's General corporate purposes Sub-total Issue expenses Total Amount as per final offer document 956.80 2,173.85 1,517.36 1,390.99 6,039 .00 210.95 6,249.95 Amount utilized at the beginning of the reported quarter 956.80 2,173.19 836.39 1,252.27 5,218.65 210.95 5,429.60 Amount utilized during the reported quarter 0.66 293.31 138.72 432.69 432.69 /all fi11ures in million) Amount utilized at the end of the reported quarter 956.80 2,173.85 1,129.70 1,390.99 5,651.34 210.95 5,862.29 Total unutilized amount as at the end of the reported quarter 387.66 387.66 387.66 6. Subsequent to the reporting date, the Group has acquired a hospital (running under the brand name of "Shantived Institute of Medical Sciences") situated at Agra, Uttar Pradesh, w.e.f February 01, 2026. The said entity has hospital with 150 operational beds (expandable upto 250 beds). 7. On November 21, 2025, the Government of India notified the four Labour Codes-namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 existing labour laws. The Ministry of Labour & Employment has issued draft Central Rules and F A Qs to facilitate assessment of the financial impact arising from the changes in regulations. The Group has evaluated the applicability and potent ial financial impact of the Labour Codes based on the draft Central Rules and FAQs and in accordance with the guidance issued by the Institute of Chartered Accountants of India. Based on such assessment, the Group·s existing wage structure is largely aligned with the definition of wages prescribed under the Labour Codes. Accordingly, the implementation of the Labour Codes does not have any material financial impact on the Group for the period ended December 31, 2025.
Page 13
The Group continues to monitor the finalisation of the Central and State Rules and any further clarifications issued by the Government and will assess and account for the impact , if any, arising from such developments as and when they occur. 8. The financial results of the Group for the quarter and nine month period ended December 31 , 2024, and year ended March 31 , 2025 were reviewed / audited by another auditor whose report dated January 27, 2025 and May 26, 2025, respectively expressed an unmodified opinion on those results/financial statements. 9. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable. 10. The aforesaid Statement is available on the Holding Company's website (www.yatharthhospitals.in) and on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com ). On behalf of the Board of Directors